European regulators have approved the anti-clotting drug ATryn for use in humans as the first medicine derived from biotech animal milk. GTC Biotherapeutics of the U.S. developed the drug for marketing by mid-2007, based on placing human genes into the DNA of goat milk, for treating people with the rare hereditary antithrombin deficiency.

Related Summaries